Skip to content

[ FUTURE OF PUBLISHING ] November 14, 2018

Researchers use machine learning and blood tests to detect cancer before symptoms appear

Researchers at the Princess Margaret Cancer Centre in Toronto today announced a new approach that shows promise for detecting cancer at a very early stage using blood tests. The method can detect cancer cells before any symptoms appear, at a stage where it is far easier to treat.

The study, published in Nature, uses a unique combination of liquid biopsy - a test that examines blood samples to determine if there are any traces of cancer DNA circulating in the blood - epigenetic alterations and machine learning. By profiling epigenetic alterations, rather than mutations, the team was able to identify thousands of modifications that are unique to different types of cancer. Then, using a machine learning approach they could create classifiers that recognize cancer cells in blood samples and determine the kind of cancer a patient is suffering from.The scientists compared the type and origin of 300 tumour samples from seven disease sites (lung, pancreatic, colorectal, breast, leukemia, bladder and kidney) with samples from healthy donors by analyzing cell-free DNA circulating in the blood plasma. In every test the circulating DNA matched the tumour DNA.

Dr. De Carvalho, Senior Scientist at Princess Margaret Cancer Centre and principal investigator of the study, said: "We are very excited at this stage. A major problem in cancer is how to detect it early. It has been a 'needle in the haystack' problem of how to find that one-in-a-billion cancer-specific mutation in the blood, especially at earlier stages, where the amount of tumour DNA in the blood is minimal."

The team is now testing their method in samples collected from healthy people that ended up developing cancer over time, including on samples from 200,000 people profiled in The Canadian Partnership of Tomorrow Project. “Over time, many of these healthy people went on to develop cancer," Dr. De Carvalho said. "The project has a blood sample from these people before they were diagnosed with cancer. So now we can test our approach on patients from this project six months to three years before the cancer develops. If we can already discover the cancer at this stage we know we have the sensitivity to perform very early-stage detection.”As a next step the researchers will bring this test to the general population.

Microscope cutting of a cell with messaging about the future of publishing infrastructure

You may also like

View all articles

3 things we learned at APE 2023

This year, the hybrid conference revisited Berlin, Germany, a familiar location for previous attendees and the Morressier team’s headquarters, ...
FUTURE OF PUBLISHING December 30, 2022

2022: A Year of Growth for Morressier

How the platform has evolved Where to begin with our platform? Our vision is a format-agnostic publishing workflow, where the entire process lives in ...
FUTURE OF PUBLISHING December 15, 2022

The year in review: Highlights on 2022 Open Access trends

What is Open Access? Before getting into detail on the Open Access trends in 2022, it's essential to understand what Open Access is and the reason ...

Public sector rationale on Open Access: facts and talking points

Scientific research users could be students, professionals, other researchers, teachers, and anyone looking to gain new knowledge about a subject. ...